Imperial College London

Professor Amanda Cross

Faculty of MedicineSchool of Public Health

Professor of Cancer Epidemiology
 
 
 
//

Contact

 

+44 (0)20 7594 3338amanda.cross

 
 
//

Assistant

 

Mr Will Kay +44 (0)20 7594 3350

 
//

Location

 

Room 1089Queen Elizabeth the Queen Mother Wing (QEQM)St Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Butt:2020:10.1158/1055-9965.EPI-19-1545,
author = {Butt, J and Jenab, M and Pawlita, M and Tjonneland, A and Kyrø, C and Boutron-Ruault, M-C and Carbonnel, F and Dong, C and Kaaks, R and Kühn, T and Boeing, H and Schulze, MB and Trichopoulou, A and Karakatsani, A and La, Vecchia C and Palli, D and Agnoli, C and Tumino, R and Sacerdote, C and Panico, S and Bueno-de-Mesquita, B and Vermeulen, R and Gram, IT and Weiderpass, E and Benjaminsen, Borch K and Quirós, JR and Agudo, A and Rodríguez-Barranco, M and Santiuste, C and Ardanaz, E and Van, Guelpen B and Harlid, S and Imaz, L and Perez-Cornago, A and Gunter, MJ and Zouiouich, S and Park, JY and Riboli, E and Cross, AJ and Heath, AK and Waterboer, T and Hughes, DJ},
doi = {10.1158/1055-9965.EPI-19-1545},
journal = {Cancer Epidemiology, Biomarkers and Prevention},
pages = {1475--1481},
title = {Antibody responses to Helicobacter pylori and risk of developing colorectal cancer in a European cohort},
url = {http://dx.doi.org/10.1158/1055-9965.EPI-19-1545},
volume = {29},
year = {2020}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - BACKGROUND: While Helicobacter pylori (H. pylori) is the major cause of gastric cancer, it has also been suggested to be involved in colorectal cancer (CRC) development. However, prospective studies addressing H. pylori and CRC are sparse and inconclusive. We assessed the association of antibody responses to H. pylori proteins with CRC in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. METHODS: We applied H. pylori multiplex serology to measure antibody responses to 13 H. pylori proteins in pre-diagnostic serum samples from 485 CRC cases and 485 matched controls nested within the EPIC study. Odds ratios (OR) and 95% confidence intervals (CI) were calculated using multivariable conditional logistic regression to estimate the association of H. pylori overall and protein-specific sero-positivity with odds of developing CRC. RESULTS: Fifty-one percent of CRC cases were H. pylori sero-positive compared to 44% of controls resulting in an OR of 1.36 (95% CI: 1.00-1.85). Among the 13 individual H. pylori proteins, the association was driven mostly by sero-positivity to Helicobacter cysteine-rich protein C (HcpC) (OR: 1.66, 95% CI: 1.19-2.30) and Vacuolating cytotoxin A (VacA) (OR: 1.34, 95% CI: 0.99-1.82), the latter being non-statistically significant only in the fully adjusted model. CONCLUSION: In this prospective multi-center European study, antibody responses to H. pylori proteins, specifically HcpC and VacA, were associated with an increased risk of developing CRC. IMPACT: Biological mechanisms for a potential causal role of H. pylori in colorectal carcinogenesis need to be elucidated, and subsequently whether H. pylori eradication may decrease CRC incidence.
AU - Butt,J
AU - Jenab,M
AU - Pawlita,M
AU - Tjonneland,A
AU - Kyrø,C
AU - Boutron-Ruault,M-C
AU - Carbonnel,F
AU - Dong,C
AU - Kaaks,R
AU - Kühn,T
AU - Boeing,H
AU - Schulze,MB
AU - Trichopoulou,A
AU - Karakatsani,A
AU - La,Vecchia C
AU - Palli,D
AU - Agnoli,C
AU - Tumino,R
AU - Sacerdote,C
AU - Panico,S
AU - Bueno-de-Mesquita,B
AU - Vermeulen,R
AU - Gram,IT
AU - Weiderpass,E
AU - Benjaminsen,Borch K
AU - Quirós,JR
AU - Agudo,A
AU - Rodríguez-Barranco,M
AU - Santiuste,C
AU - Ardanaz,E
AU - Van,Guelpen B
AU - Harlid,S
AU - Imaz,L
AU - Perez-Cornago,A
AU - Gunter,MJ
AU - Zouiouich,S
AU - Park,JY
AU - Riboli,E
AU - Cross,AJ
AU - Heath,AK
AU - Waterboer,T
AU - Hughes,DJ
DO - 10.1158/1055-9965.EPI-19-1545
EP - 1481
PY - 2020///
SN - 1055-9965
SP - 1475
TI - Antibody responses to Helicobacter pylori and risk of developing colorectal cancer in a European cohort
T2 - Cancer Epidemiology, Biomarkers and Prevention
UR - http://dx.doi.org/10.1158/1055-9965.EPI-19-1545
UR - https://www.ncbi.nlm.nih.gov/pubmed/32332031
UR - https://cebp.aacrjournals.org/content/29/7/1475
UR - http://hdl.handle.net/10044/1/79770
VL - 29
ER -